Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HIMS

The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic

Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.

MarketBeat

Bearish Pressure Is Building Around These 3 Stocks

Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.

MarketBeat

FTC Alleges a Telehealth Company Sent Users' Health Conditions to Ad Platforms After Promising Discretion

The FTC sued Hims and Hers over alleged sharing of sensitive health data with ad platforms. What the complaint alleges and how to check your own accounts.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

Barchart

A Hims cofounder fired his marketing agency for an AI-powered team. Now his 24/7 online vet service is growing 20% a month

Joe Spector helped build a multibillion-dollar telehealth company. Now he’s on to own remote vet services.

Fortune

HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the news means for HIMS stock.

Barchart

The FDA’s peptide vote could create telehealth's next multibillion-dollar market

As regulators weigh whether pharmacies can legally compound wellness peptides, companies are preparing for a repeat of the GLP-1 boom—only this time with even murkier science.

Fortune

Read news from The Economist, FT, and more,
with one subscription

As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

MarketBeat

FDA to discuss easing restrictions on peptides despite safety concerns

Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy

The Guardian - US

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

MarketBeat

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

MarketBeat

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

Barchart

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

MarketBeat

Hims & Hers Health Q1 Earnings Call Highlights

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to know

Hims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and revenue below expectations. Despite these weak results, the company raised its full-year revenue outlook and projected strong second-quarter revenue, as it navigates regulatory scrutiny around weight-loss drugs.

MarketBeat

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

MarketBeat

Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.

Barchart

Should You Buy HIMS Stock Following Friday's Rally?

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

Get all your
news in one place.

100's of premium titles.
One news app.

Axios

RFK Jr.'s peptide push could become next wellness boom

The heavily touted but loosely regulated proteins could fuel the kind of boom we've seen with weight-loss drugs.

Barchart

RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?

Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain unattractive to own in 2026.

MarketBeat

3 Sectors to Buy While They're Down and 1 to Walk Away From

Jeff Clark and Andy Swan share three beaten-down sectors with contrarian upside and one popular sector to avoid, plus specific stock picks in financials, healthcare, and software.

MarketBeat

MarketBeat Week in Review – 03/09 - 03/13

Stocks moved higher this week despite uncertainty over the Iran conflict and oil prices; economic indicators point to no change in interest rates next week

Barchart

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

MarketBeat

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

International Business Times

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations